Publications by authors named "Liselotte Tas"

Claim this Profile
T
Tumour-reactive heterotypic CD8 T cell clusters from clinical samples.
Sofía Ibáñez-Molero, Johanna Veldman, Juan Simon Nieto, Joleen J H Traets, Austin George, Liselotte Tas

Nature· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial.
Liselotte Tas, Marie B Weitemeyer, Maartje W Rohaan, Troels H Borch, Alexander C J van Akkooi

Br J Surg· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.
Catriona Harvey, Kazi J Nahar, Janet McKeown, Serigne N Lo, Sheima Farag, Liselotte Tas, Roberto Martín Huertas

J Immunother Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers.
Liselotte Tas, Inge Jedema, John B A G Haanen

Curr Opin Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy.
Kim E Kortekaas, Saskia J Santegoets, Liselotte Tas, Ilina Ehsan, Pornpimol Charoentong

J Immunother Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fatigue in Sjögren's Syndrome: A Search for Biomarkers and Treatment Targets.
Iris L A Bodewes, Peter J van der Spek, Leticia G Leon, Annemarie J M Wijkhuijs, Cornelia G van Helden-Meeuwsen, Liselotte Tas

Front Immunol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis.
Iris L A Bodewes, Erika Huijser, Cornelia G van Helden-Meeuwsen, Liselotte Tas, Ruth Huizinga

J Autoimmun· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis